Roth MKM initiated coverage of Reviva Pharmaceuticals with a Buy rating and $12 price target. The analyst believes the company’s developmental drug brilaroxazine will have positive Phase 3 clinical data in October, ultimately achieve FDA approval, and generate significant revenues. The shares should be considered speculative with binary risk on clinical data and heightened financial risk, however, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RVPH:
- Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- Reviva Pharmaceuticals: Enrollment complete in Phase 3 RECOVER study
- Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia
- Reviva Pharmaceuticals reports Q2 EPS (55c), consensus (28c)
- Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights